Bridging Therapy Response and Pre-Lymphodepletion Plasma Cell Burden As Determinants of Ciltacabtagene Autoleucel Safety and Efficacy Outcomes in relapsed/refractory Multiple Myeloma

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Doris K. Hansen, Brett Reid, Ariel Felipe Grajales-Cruz, Peter K.C. Cheng, Zhuoer Xie, Brandon Jamaal Blue, Laura B Oswald, Dae Hyun Lee, Gabriel De Avila, David Scheiber-Camoretti, Ken Harada, Daniel Deavila
+23 more Brandon J. Kale, Karla Feliciano Salva, David Kaldas, Kristy Matte, Fabiana Perna, Rebecca M. Gonzalez, Lin Fan, Victoria R. Alegria, Matthew Perciavalle, Helen Pai, Todd Stinard, Mukta Sharma, Kevin C. De Braganca, Zaina P. Qureshi, Hien Liu, Kenneth H Shain, Rachid C Baz, Taiga Nishihori, Melissa Alsina, Ciara Louise Freeman, Omar Alexis Castaneda Puglianini, Frederick Lundry Locke, Lauren Cole Peres
DOI: 10.1016/j.jtct.2025.12.224
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S164–S164
Publication date
1 February 2026
Language
EN